An observational study in T1 Gastric Cancer Lymph Node Metastasis Early Gastric Cancer Artificial Intelligence-Assisted Diagnosis Multimodal Data Integration, sponsored by Qun Zhao. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-08-15.
Sponsored by Qun Zhao · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 487 studies in Neoplasm Metastasis with a site in China — 224 open to participants now, 264 under way, 40 of them phase 3. Neoplasm Metastasis · China.
Among the 487 studies in Neoplasm Metastasis with a site in China, this one is the 30th largest by planned enrollment of the 83 observational ones that give a count, is one of 62 that started in 2025, is one of 83 observational ones, reaches primary completion later than 53 of the 263 other live ones, and was the 393rd registered.
4,052 studies on the registry are indexed under Neoplasm Metastasis; 891 are open to participants now.
Browse Neoplasm Metastasis studies →224 of the 487 studies in Neoplasm Metastasis with a site in China are open now. Recruiting first, the newest first:
Genovn Therapeutics (Suzhou) Co., Ltd. · Sites in China
Ages 18–70
Fudan University · Sites in China
Ages 18–75
Nanjing Medical University · Sites in China
Ages 18–80
Fudan University · Sites in China
Ages 18–75
Taizhou Mabtech Pharmaceutical Co.,Ltd · Sites in China
Ages 18+
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 692 Neoplasm Metastasis studies recruiting now, 539 (78%) set no upper age limit and 96 (14%) stop at 75 or younger; 47 take children under 18; 18 take healthy volunteers.
This study: 18 Years and older · all sexes.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
487 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 142 · Phase 2 171 · Phase 3 85 · Phase 4 13
First in 2003; this study’s year is marked. 62 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 300 is above the median of 137 across 561 observational studies indexed under Neoplasm Metastasis.
Median enrollment 90 across the 403 interventional studies, 180 across the 83 observational. Of the 104 that completed or were terminated, 27 (26%) have results posted.
This tab as a report to print or save as PDF → With an account.
172 of 487 have an industry lead sponsor. The 10 most frequent:
Qun Zhao is the lead sponsor of 16 studies on the registry; 10 are open to participants now.
Qun Zhao has 2 studies filed under Neoplasm Metastasis — fewer than ten, so there is no comparison to draw.
81 of the studies in Neoplasm Metastasis with a site in China that are under way reach primary completion within a year, 8 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07162883Phase 3Qilu Pharmaceutical Co., Ltd.Pharmacokinetic Study of QL2107 Versus Keytruda® for Adjuvant Therapy of Non-Small Cell Lung Cancer (NSCLC) | 2026-12-31 |
| NCT03303495Phase 3Sun Yat-sen UniversityA Study of 2nd-line FOLFIRI ± Bevacizumab vs. Irinotecan ± Bevacizumab in mCRC | 2026-12-31 |
| NCT05794971Phase 3Sun Yat-sen UniversityRegorafenib Combined With Irinotecan Drug-Eluting Beads for Colorectal Cancer Liver Metastases | 2027-03-31 |
| NCT04784715Phase 3AstraZenecaTrastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer (DESTINY-Breast09) | 2027-05-03 |
| NCT06961188Phase 3Changchun GeneScience Pharmaceutical Co., Ltd.Clinical Study on Nanocrystalline Megestrol Acetate for Appetite Improvement and Weight Gain in Pre-Cachexia and Cachexia Stages Key Terminology Analysis | 2027-06-30 |
Add all 81 to your calendar (.ics) → With an account.
Among the 487 studies in Neoplasm Metastasis with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study aims to develop and validate an artificial intelligence (AI) model that integrates clinical, pathological, and imaging data to predict the presence of lymph node metastasis (LNM) in patients with T1-stage gastric cancer.
The study will also compare the diagnostic performance of physicians with and without AI assistance, including clinicians with varying levels of experience.
The goal is to improve early decision-making and support more personalized treatment strategies for patients with early gastric cancer.
Patients diagnosed with T1-stage gastric adenocarcinoma who undergo radical gastrectomy with lymph node dissection at participating centers. Participants must have available preoperative clinical, imaging, and pathological data for AI model input and postoperative histopathological confirmation of lymph node status.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Age 18 years or older
confirmed primary gastric adenocarcinoma
Clinical stage T1 (T1a or T1b) confirmed by endoscopy and imaging
Undergoing radical gastrectomy with lymph node dissection
Preoperative data available: clinical variables, CT imaging, and pathology slides
Written provided
Exclusion Criteria:
History of other within the past 5 years
Received chemotherapy or radiotherapy
Incomplete clinical or pathological data
Poor quality or missing CT or histopathology images
Patients with distant (M1) at diagnosis
Inability or refusal to provide
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
This intervention involves the use of a custom-built artificial intelligence (AI) diagnostic model that integrates multimodal data-including clinical variables, histopathological features, and imaging data-to predict lymph node metastasis in patients with T1-stage gastric cancer. The model provides risk probability scores and classification outputs that assist physicians in diagnostic decision-making. The AI system will be compared with physician performance at different levels of experience (resident, attending, senior) to assess its impact on diagnostic accuracy and clinical decision support.
Diagnostic Accuracy of the AI Model for Predicting Lymph Node Metastasis in T1 Gastric Cancer
Time frame: Immediately after surgery (within 7 days postoperatively, based on final pathological report)
Diagnostic Accuracy of the AI Model for Predicting Lymph Node Metastasis in T1 Gastric Cancer
Time frame: At the time of final pathological diagnosis (typically within 3-7 days after surgery)
Plan to share: Undecided
No publications or documents are linked to this record.
Started Jan 2025 (actual). Primary completion is estimated for Dec 2025, 11 months after the start.
Of 211 non-industry observational studies under Neoplasm Metastasis, half reached primary completion within 74 months of starting (the median), counting those still running; a quarter within 36 and three quarters within 172. This study's planned 11 months is below that.
Counting every sponsor, half of 242 studies reached it within 66 months; a quarter within 35 and three quarters within 172.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Qun Zhao